Pimagedine: a novel therapy for diabetic nephropathy
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Hyperglycaemia is directly involved in causing long-term diabetic complications. The non-enzymatic glycation of proteins, yielding irreversible advanced glycation end products and advanced glycation end products-derived protein crosslinking, participates in the development of diabetic complications, such as diabetic nephropathy. Diabetic nephropathy is becoming a major medical problem with increasing numbers of these patients progressing to end stage renal disease, thus requiring renal replacement therapy. While several interventions may slow the development and progression of diabetic nephropathy, there is no effective treatment to prevent or reverse the disease. Pimagedine (aminoguanidine HCl) has been shown to be an effective agent in reducing the severity of the structural and functional alterations associated with experimental diabetic nephropathy. Preliminary studies suggest a beneficial effect of pimagedine in treating patients with diabetic nephropathy. In summary, these observations support a role for advanced glycation end products inhibitors, like pimagedine, in the management of diabetic nephropathy, either alone or in combination with other therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987 · cited 4×
“control, interruption of the RAS using angiotensin-converting enzyme inhibitors (ACEIs) [5,6] and angiotensin 1 (AT1) receptor blockers (ARB) [7,8], along with dietary modification [9] and cholesterol-lowering agents.”
MethodInfluentialThe effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Role of oxidative stress in diabetic complications: a new perspective on an old paradigm.
Baynes, J. W., & Thorpe, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.1 · Cited by 2,441 · cited 1×
“ALEs can affect the structure and function of vascular walls setting the stage for atherosclerosis [45,46].”
BackgroundKoschinsky, T., He, C.-J., Mitsuhashi, T., Bucala, R., Liu, C., Buenting, C., Heitmann, K., & Vlassara, H. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.12.6474 · Cited by 792
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694 · cited 2×
“The Diabetes Control and Complications Trial (DCCT) [1,2] and United Kingdom Prospective Diabetic Study (UKPDS) [4] have demonstrated that intensive control of blood glucose concentration can retard development or progression of diabetic complications, such as retinopathy, neuropathy and presence of microalbuminuria i…”
Background
Cited by
Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P.-H., & Cooper, M. E. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.18 · Cited by 1,230
Williams, M. E., Bolton, W. K., Khalifah, R. G., Degenhardt, T. P., Schotzinger, R. J., & McGill, J. B. (2007) · American Journal of Nephrology · doi:10.1159/000108104 · Cited by 253
Self-citationWendt, T., Tanji, N., Guo, J., Hudson, B. I., Bierhaus, A., Ramasamy, R., Arnold, B., Nawroth, P. P., Yan, S. F., D’Agati, V., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000065100.17349.ca · Cited by 239
Kidney, heart and brain: three organs targeted by ageing and glycation
Frimat, M., Daroux, M., Litke, R., Nevière, R., Tessier, F. J., & Boulanger, E. (2017) · Clinical Science · doi:10.1042/cs20160823 · Cited by 88
Chen, H., Virk, M. S., & Chen, F. (2016) · International Journal of Food Sciences and Nutrition · doi:10.3109/09637486.2016.1166187 · Cited by 65
“Pimagedine was the first AGEs inhibitor engaged in clinical research and was discontinued due to the side effects (myocardial infarction, congestive heart failure and atrial fibrillation) during phase-III clinical trial in patients with diabetic nephropathy (Bolton & Abdel-Rahman 2002).”
Background
Metadata
- Authors
- Bolton, W. K., & Abdel-Rahman, E.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2002-04
- Volume
- 11
- Issue
- 4
- Pages
- 565-574
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2168017441
- Cited by
- 82
- References
- 5
- FWCI
- 3.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pimagedine: a novel therapy for diabetic nephropathy. https://app.cochat.ai/papers/10.1517/13543784.11.4.565
- The paper
- Bolton, W. K., & Abdel-Rahman, E. (2002). Pimagedine: a novel therapy for diabetic nephropathy. Expert Opinion on Investigational Drugs. https://doi.org/10.1517/13543784.11.4.565
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.